CuraCell selects IKF as CRO partner for its phase 1/2a trial

CuraCell has signed a partnership agreement with the German Clinical Research Organisation, IKF, located in Frankfurt, Germany. IKF will support CuraCell in the preparation of the upcoming phase 1/2a trial and coordinate clinical operations throughout the trial.

IKF is specialized in investigator-initiated and industry-academia collaborative cancer research. Founded by oncologists, with more than 20 years of operations, the company has been involved in oncology trials across 300 centers world-wide.